Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,630 total articles
Context Therapeutics announced the first patient dosing in the Phase 1 clinical trial of CT-202, their Nectin-4 x CD3 T cell engaging bispecific antibody, designed as a monotherapy for patients with Nectin-4-positive urothelial, colorectal, and triple-negative breast cancers. The trial aims to evaluate the safety, tolerability, pharmacokinetics, an…
Orion180 Insurance Group Inc., a rapidly growing specialty insurance provider focused on homeowners and flood insurance, announced the launch of its initial public offering (IPO) of up to 20 million shares on the Nasdaq under the ticker OIG. The offering is expected to price between $15.00 and $17.00 per share. Orion180 utilizes a proprietary techn…
TransUnion released findings from a Forrester-commissioned study showing increased frequency and impact of cyberattacks, with 60% of organizations experiencing at least one material incident in the past 18 months. The study highlights gaps in incident response readiness, the need for expert partners, and strategies to improve organizational resilie…
Gilat Satellite Networks announced that its subsidiary, Gilat DataPath, received an over $32 million order from the U.S. Department of War for multi-band Deployable Ku/Ka/X-band Earth Terminals (DKET) systems. These relocatable ground platforms support rapid deployment and resilience in mission-critical defense communications, reinforcing Gilat Def…
Bilibili Inc. has completed a $500 million offering of convertible senior notes due 2031, alongside a concurrent equity placement and share repurchases. The offering involved qualified institutional buyers outside the US, and Tencent subscribed to an additional $200 million in notes subject to shareholder approval. The company also repurchased shar…
CoinShares PLC announced that CEO Jean-Marie Mognetti will attend the Oppenheimer Fintech Leaders Conference in New York on September 15, 2026. He will conduct one-on-one meetings with investors, discussing the company's business, recent progress, and industry outlook. The company specializes in digital asset management and is publicly listed on Na…
Opus Genetics announced positive interim data from the low-dose cohort of its ongoing Phase 1/2 trial for OPGx-BEST1, a gene therapy targeting BEST1-related inherited retinal diseases. All participants showed meaningful improvements in visual function, with favorable safety and structural retinal improvements also reported. The company achieved ali…
Tilray Brands' subsidiary, Breckenridge Distillery, introduces a limited-edition whiskey collection honoring 40 years of 'The Drive' and its partnership with the Denver Broncos. The collection includes award-winning bourbon blends and a nostalgic whiskey seltzer, available in Colorado to enhance Broncos game-day experiences. This launch underscores…
Actuate Therapeutics reported promising preclinical data demonstrating that elraglusib, a GSK-3β inhibitor, when combined with RAS inhibitors zoldonrasib and daraxonrasib, exhibits synergistic antitumor activity in multiple murine and human pancreatic cancer models, including those resistant to FOLFIRINOX chemotherapy. These results, supported by i…
MapLight Therapeutics, a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, announced its management team's participation in the Morgan Stanley 24th Annual Global Healthcare Conference. The company aims to highlight its innovative discovery platform targeting neural circuits linked to diseases,…
Lightbridge Corporation has secured access to the Advanced Test Reactor (ATR) loop testing facility at Idaho National Laboratory to irradiate its Lightbridge Fuel™ rodlets under commercial reactor conditions. This milestone enables critical data collection for fuel performance validation and supports progression toward fuel qualification and commer…
Destination XL Group, Inc., a leading Big + Tall men's apparel retailer, reported Q2 FY2026 sales of $111.6 million, a 3.4% decline from the prior year, with comparable sales down 3.5%. Despite sales pressure and ongoing economic headwinds, net income improved to $2.0 million aided by a $4.6 million tariff refund. The company is focusing on strateg…
SailPoint, Inc., a leader in enterprise identity security, announced its financial results for the fiscal second quarter ended July 31, 2026, and hosted a conference call to discuss its performance and outlook. The company emphasizes its role in securing digital and human identities for modern enterprises through its identity-first security platfor…
Fate Therapeutics announced the presentation of clinical and pre-clinical data for its off-the-shelf CAR T-cell therapies FT819 and FT839 at the Congress of Clinical Rheumatology West meeting. The Phase 1 trial data for FT819 demonstrates favorable safety, early and sustained efficacy in systemic lupus erythematosus (SLE) patients, supporting advan…
Radiopharm Theranostics announced positive Phase 1 trial results for RAD301, a novel Gallium-68 labeled peptide targeting αvβ6-integrin in pancreatic ductal adenocarcinoma (PDAC) patients. The trial demonstrated favorable safety, significant tumor uptake, and selective biodistribution, indicating RAD301’s potential to improve pancreatic cancer imag…
Balchem Corporation, a global specialty ingredient manufacturer serving health and nutrition markets, announced its participation in the 9th Annual Wells Fargo Consumer Conference. Senior executives including the CEO, CFO, and Senior Director of Investor Relations will present, highlighting the company's multi-segment operations across human nutrit…
Fractyl Health, a clinical-stage metabolic therapeutics company targeting obesity and type 2 diabetes, announced CEO Dr. Harith Rajagopalan will present and engage in meetings at the H.C. Wainwright and Morgan Stanley healthcare investment conferences in September 2026. The events will be webcast and focus on the company’s advanced metabolic diseas…
ODDITY Tech Ltd. reported Q2 2026 net revenue of $181 million, down 25% year-over-year, with adjusted EBITDA of $13 million and net income of $13 million. The company highlighted strong revenue growth in its SpoiledChild brand and promising early results from METHODIQ. It is addressing a technical advertising issue with its largest partner affectin…
X4 Pharmaceuticals, a US-based biotech firm focused on rare hematology diseases, will take part in a management fireside chat at the 2026 Wells Fargo Healthcare Conference. The company is developing and commercializing mavorixafor, an oral CXCR4 antagonist currently approved in the US and undergoing pivotal Phase 3 trials for chronic neutropenia. T…
Autolus Therapeutics announced that the FDA granted RMAT designation to its T cell therapy candidate obecabtagene autoleucel (obe-cel) for treating systemic lupus erythematosus (SLE) and lupus nephritis (LN), accelerating development and regulatory review. The company plans further clinical data presentations and continues enrollment in a pivotal P…
Pyxis Oncology reported positive updated results from its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The study showed a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months,…
Rezolute announced that the FDA review of their Phase 3 sunRIZE study data for their drug ersodetug in treating congenital hyperinsulinism (HI) is ongoing without a defined timeline. While the study did not meet its primary endpoint for statistical significance, secondary analyses indicate glycemic improvements. The open-label extension phase conti…
Kura Oncology has established Caspian Therapeutics, a separately financed subsidiary focused on advancing KO-7246, a next-generation menin inhibitor designed for diabetes and cardiometabolic diseases. Caspian raised $50 million led by BVF Partners and supported by key biotech investors including Eli Lilly. Preclinical studies show promising results…
Satellos Bioscience announced that their lead oral small molecule drug candidate, previously known as SAT-3247, has been assigned the International Nonproprietary Name (INN) 'forazapadin.' The drug targets AAK1 to promote muscle regeneration and is currently in Phase 2 clinical trials for Duchenne muscular dystrophy (DMD), with plans to initiate a …
Aya Gold & Silver released an updated 2026 Preliminary Economic Assessment for its Boumadine polymetallic project in Morocco, showing a more than doubling of the after-tax net present value to $3.5 billion and an internal rate of return of 93%. The project life extends to 14 years with improved payable metal production and capital efficiency. The u…
